Published in Yale J Biol Med on December 01, 2006
Beyond the zebrafish: diverse fish species for modeling human disease. Dis Model Mech (2013) 1.19
The history of tumor virology. Cancer Res (2008) 1.14
Chronic viral infection and primary central nervous system malignancy. J Neuroimmune Pharmacol (2010) 0.84
Construction and identification of recombinant lentiviral vector containing HIV-1 Tat gene and its expression in 293T cells. J Biomed Res (2010) 0.81
JC polyomavirus in the aetiology and pathophysiology of glial tumours. Neurosurg Rev (2015) 0.78
Immunotherapy against cancer-related viruses. Cell Res (2016) 0.75
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers. Front Oncol (2017) 0.75
Regulation of the metastasis suppressor Nm23-H1 by tumor viruses. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Hepatocellular carcinoma. Lancet (2003) 22.54
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (1998) 5.24
Viruses in human cancers. Science (1991) 4.58
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med (2002) 4.33
Hepatitis C: global prevalence. Wkly Epidemiol Rec (1997) 3.95
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst (2000) 3.77
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41
Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med (1999) 3.38
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature (1998) 2.76
Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med (2001) 2.55
HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA. Blood (1988) 2.30
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood (2001) 2.20
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet (2002) 1.91
Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res (1988) 1.89
Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol (2004) 1.81
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov (2002) 1.73
Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol (1982) 1.69
An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (1978) 1.48
Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res (1999) 1.35
Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer (1994) 1.27
Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res (1983) 1.25
First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand (1995) 1.25
Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr (2003) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22
Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis (2006) 1.19
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res (2002) 1.15
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res (2006) 1.11
Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol (1986) 1.10
Treating hepatitis C infection in liver transplant recipients. Liver Transpl (2006) 1.09
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 1.05
Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol (2006) 1.04
Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine (1999) 0.95
Prevention of mortality from hepatitis B and hepatitis C. Lancet (2006) 0.90
The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Med (2006) 0.90
Control of hepatitis B in the United Kingdom. Vaccine (1998) 0.89
Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK). Vaccine (1998) 0.81
Advances in HTLV-1 peptide vaccines and therapeutics. Curr Protein Pept Sci (2006) 0.76